Dose-finding study on fleroxacin in chronic respiratory tract infection

Kohei Hara; Masaki Hirota; Keizo Yamaguchi; Shigeru Kohno; Toshiaki Hayashi; Yasumasa Doutsu; Kouichi Watanabe; Hiroshi Mukai; Yuuichi Inoue; Koichiro Nakata; Tatsuo Nakatani; Yoshitaka Nakamori; Naohiko Chonabayashi; Masayuki Noguchi; Kohji Narui; Akira Saito; Masumi Tomizawa; Ichiro Nakayama; Shoichiro Irimajiri; Mitsuo Obana; Kotaro Oizumi; Akira Watanabe; Seiichi Aonuma; Masakichi Motomiya; Kiyoshi Konno; Kohsaku Nagai; Shigeru Shimoda; Izumi Hayashi; Kikuo Ohnuma; Miki Hasuike; Masataka Katsu; Shinji Okui; Toshio Fukui; Hiroshi Hirose; Hiroyuki Kobayashi; Hiroshi Oshitani; Jingoro Shimada; Kohya Shiba; Masanobu Kaji; Atsushi Saito; Osamu Sakai; Kaoru Shimada; Takashi Inamatsu; Hideo Ikemoto; Kazuyoshi Watanabe; Tomoo Kohara; Takao Ohkubo; Hirotada Ikeda; Fumio Matsumoto; Takeo Imai; Shigeki Odagiri; Kaneo Suzuki; Kou Murohashi; Atuhiko Sato; Akihiko Okano; Hirokazu Okano; Masami Taniguchi; Fumio Miki; Rinzo Soejima; Niro Okimoto; Jiro Hino; Yoshihisa Nakagawa; Toshiharu Matsushima; Yoshihiko Tano; Michio Yamakido; Shinichi Ishioka; Masaru Nasu; Tohru Yamazaki; Hideaki Shigeno; Jun Goto; Takayoshi Tashiro; Keizo Matsumoto; Tsuyoshi Nagatake; Naoto Rikitomi; Kazunori Oishi; Atsushi Saito; Yoshihiro Shigeno; Yuei Irabu; Hiroshi Kohatsu; Junichi Ohshiro; Nobuya Ogawa; Koichi Deguchi

doi:10.11250/chemotherapy1953.38.Supplement2_454

Dose-finding study on fleroxacin in chronic respiratory tract infection

Kohei Hara, Masaki Hirota, Keizo Yamaguchi, Shigeru Kohno, Toshiaki Hayashi, Yasumasa Doutsu, Kouichi Watanabe, Hiroshi Mukai, Yuuichi Inoue, Koichiro Nakata, Tatsuo Nakatani, Yoshitaka Nakamori, Naohiko Chonabayashi, Masayuki Noguchi, Kohji Narui, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Shoichiro Irimajiri, Mitsuo ObanaKotaro Oizumi, Akira Watanabe, Seiichi Aonuma, Masakichi Motomiya, Kiyoshi Konno, Kohsaku Nagai, Shigeru Shimoda, Izumi Hayashi, Kikuo Ohnuma, Miki Hasuike, Masataka Katsu, Shinji Okui, Toshio Fukui, Hiroshi Hirose, Hiroyuki Kobayashi, Hiroshi Oshitani, Jingoro Shimada, Kohya Shiba, Masanobu Kaji, Atsushi Saito, Osamu Sakai, Kaoru Shimada, Takashi Inamatsu, Hideo Ikemoto, Kazuyoshi Watanabe, Tomoo Kohara, Takao Ohkubo, Hirotada Ikeda, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Kaneo Suzuki, Kou Murohashi, Atuhiko Sato, Akihiko Okano, Hirokazu Okano, Masami Taniguchi, Fumio Miki, Rinzo Soejima, Niro Okimoto, Jiro Hino, Yoshihisa Nakagawa, Toshiharu Matsushima, Yoshihiko Tano, Michio Yamakido, Shinichi Ishioka, Masaru Nasu, Tohru Yamazaki, Hideaki Shigeno, Jun Goto, Takayoshi Tashiro, Keizo Matsumoto, Tsuyoshi Nagatake, Naoto Rikitomi, Kazunori Oishi, Atsushi Saito, Yoshihiro Shigeno, Yuei Irabu, Hiroshi Kohatsu, Junichi Ohshiro, Nobuya Ogawa, Koichi Deguchi

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

To objectively evaluate the appropriate clinical dose of fleroxacin, a new quinolone antibacterial agent, in the treatment of chronic respiratory tract infections, we carried out a dose-finding comparative study using ofloxacin (OFLX) as the control drug. Patients were given fleroxacin at a single daily dose of 200 mg or 300mg or 600mg of OFLX (t. i. d.) for 14 days in principle. The following results were obtained. 1. The clinical efficacy rates (including excellent and good) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 90.0%(36/40) in the fleroxacin 300 mg group and 77.3%(34/44) in the OFLX group. There was a significant difference between the 200 mg and 300 mg fleroxacin groups. 2. Bacteriologically, the eradication rates were 65.4%(17/26) in the fleroxacin 200 mg group, 73.9%(17/23) in the fleroxacin 300 mg group and 75.9%(22/29) in the OFLX group. 3. The incidence of side effects was 8.5%(4/47) in the fleroxacin 200 mg group, 9.5%(4/42) in the fleroxacin 300 mg group and 4.3%(2/46) in the OFLX group. They were not serious in degree. 4. The incidence of abnormal changes in laboratory test values was 7.1%(3/42) in the fleroxacin 200 mg group, 8.3%(3/36) in the fleroxacin 300 mg group and 25.6%(11/43) in the OFLX group. All changes were mild in degree. 5. The utility rates (including markedly useful and useful) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 85.4%(35/41) in the fleroxacin 300 mg group and 75.6%(34/45) in the OFLX group. There was a significant difference between the 200mg and 300 mg fleroxacin groups. Our results suggest that a daily dose of 300mg of fleroxacin is a suitable clinical dosage in treating chronic respiratory tract infections.

Original language	English
Pages (from-to)	454-471
Number of pages	18
Journal	Chemotherapy
Volume	38
DOIs	https://doi.org/10.11250/chemotherapy1953.38.Supplement2_454
Publication status	Published - 1990
Externally published	Yes

Keywords

Chronic respiratory tract infection
Dose-finding study
Fleroxacin

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.38.Supplement2_454

Cite this

Hara, K., Hirota, M., Yamaguchi, K., Kohno, S., Hayashi, T., Doutsu, Y., Watanabe, K., Mukai, H., Inoue, Y., Nakata, K., Nakatani, T., Nakamori, Y., Chonabayashi, N., Noguchi, M., Narui, K., Saito, A., Tomizawa, M., Nakayama, I., Irimajiri, S., ... Deguchi, K. (1990). Dose-finding study on fleroxacin in chronic respiratory tract infection. Chemotherapy, 38, 454-471. https://doi.org/10.11250/chemotherapy1953.38.Supplement2_454

Hara, K, Hirota, M, Yamaguchi, K, Kohno, S, Hayashi, T, Doutsu, Y, Watanabe, K, Mukai, H, Inoue, Y, Nakata, K, Nakatani, T, Nakamori, Y, Chonabayashi, N, Noguchi, M, Narui, K, Saito, A, Tomizawa, M, Nakayama, I, Irimajiri, S, Obana, M, Oizumi, K, Watanabe, A, Aonuma, S, Motomiya, M, Konno, K, Nagai, K, Shimoda, S, Hayashi, I, Ohnuma, K, Hasuike, M, Katsu, M, Okui, S, Fukui, T, Hirose, H, Kobayashi, H, Oshitani, H, Shimada, J, Shiba, K, Kaji, M, Saito, A, Sakai, O, Shimada, K, Inamatsu, T, Ikemoto, H, Watanabe, K, Kohara, T, Ohkubo, T, Ikeda, H, Matsumoto, F, Imai, T, Odagiri, S, Suzuki, K, Murohashi, K, Sato, A, Okano, A, Okano, H, Taniguchi, M, Miki, F, Soejima, R, Okimoto, N, Hino, J, Nakagawa, Y, Matsushima, T, Tano, Y, Yamakido, M, Ishioka, S, Nasu, M, Yamazaki, T, Shigeno, H, Goto, J, Tashiro, T, Matsumoto, K, Nagatake, T, Rikitomi, N, Oishi, K, Saito, A, Shigeno, Y, Irabu, Y, Kohatsu, H, Ohshiro, J, Ogawa, N & Deguchi, K 1990, 'Dose-finding study on fleroxacin in chronic respiratory tract infection', Chemotherapy, vol. 38, pp. 454-471. https://doi.org/10.11250/chemotherapy1953.38.Supplement2_454

@article{e2e7cf6f3aea4d1c9498dc689e8d3fb0,

title = "Dose-finding study on fleroxacin in chronic respiratory tract infection",

abstract = "To objectively evaluate the appropriate clinical dose of fleroxacin, a new quinolone antibacterial agent, in the treatment of chronic respiratory tract infections, we carried out a dose-finding comparative study using ofloxacin (OFLX) as the control drug. Patients were given fleroxacin at a single daily dose of 200 mg or 300mg or 600mg of OFLX (t. i. d.) for 14 days in principle. The following results were obtained. 1. The clinical efficacy rates (including excellent and good) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 90.0%(36/40) in the fleroxacin 300 mg group and 77.3%(34/44) in the OFLX group. There was a significant difference between the 200 mg and 300 mg fleroxacin groups. 2. Bacteriologically, the eradication rates were 65.4%(17/26) in the fleroxacin 200 mg group, 73.9%(17/23) in the fleroxacin 300 mg group and 75.9%(22/29) in the OFLX group. 3. The incidence of side effects was 8.5%(4/47) in the fleroxacin 200 mg group, 9.5%(4/42) in the fleroxacin 300 mg group and 4.3%(2/46) in the OFLX group. They were not serious in degree. 4. The incidence of abnormal changes in laboratory test values was 7.1%(3/42) in the fleroxacin 200 mg group, 8.3%(3/36) in the fleroxacin 300 mg group and 25.6%(11/43) in the OFLX group. All changes were mild in degree. 5. The utility rates (including markedly useful and useful) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 85.4%(35/41) in the fleroxacin 300 mg group and 75.6%(34/45) in the OFLX group. There was a significant difference between the 200mg and 300 mg fleroxacin groups. Our results suggest that a daily dose of 300mg of fleroxacin is a suitable clinical dosage in treating chronic respiratory tract infections.",

keywords = "Chronic respiratory tract infection, Dose-finding study, Fleroxacin",

author = "Kohei Hara and Masaki Hirota and Keizo Yamaguchi and Shigeru Kohno and Toshiaki Hayashi and Yasumasa Doutsu and Kouichi Watanabe and Hiroshi Mukai and Yuuichi Inoue and Koichiro Nakata and Tatsuo Nakatani and Yoshitaka Nakamori and Naohiko Chonabayashi and Masayuki Noguchi and Kohji Narui and Akira Saito and Masumi Tomizawa and Ichiro Nakayama and Shoichiro Irimajiri and Mitsuo Obana and Kotaro Oizumi and Akira Watanabe and Seiichi Aonuma and Masakichi Motomiya and Kiyoshi Konno and Kohsaku Nagai and Shigeru Shimoda and Izumi Hayashi and Kikuo Ohnuma and Miki Hasuike and Masataka Katsu and Shinji Okui and Toshio Fukui and Hiroshi Hirose and Hiroyuki Kobayashi and Hiroshi Oshitani and Jingoro Shimada and Kohya Shiba and Masanobu Kaji and Atsushi Saito and Osamu Sakai and Kaoru Shimada and Takashi Inamatsu and Hideo Ikemoto and Kazuyoshi Watanabe and Tomoo Kohara and Takao Ohkubo and Hirotada Ikeda and Fumio Matsumoto and Takeo Imai and Shigeki Odagiri and Kaneo Suzuki and Kou Murohashi and Atuhiko Sato and Akihiko Okano and Hirokazu Okano and Masami Taniguchi and Fumio Miki and Rinzo Soejima and Niro Okimoto and Jiro Hino and Yoshihisa Nakagawa and Toshiharu Matsushima and Yoshihiko Tano and Michio Yamakido and Shinichi Ishioka and Masaru Nasu and Tohru Yamazaki and Hideaki Shigeno and Jun Goto and Takayoshi Tashiro and Keizo Matsumoto and Tsuyoshi Nagatake and Naoto Rikitomi and Kazunori Oishi and Atsushi Saito and Yoshihiro Shigeno and Yuei Irabu and Hiroshi Kohatsu and Junichi Ohshiro and Nobuya Ogawa and Koichi Deguchi",

year = "1990",

doi = "10.11250/chemotherapy1953.38.Supplement2_454",

language = "English",

volume = "38",

pages = "454--471",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Dose-finding study on fleroxacin in chronic respiratory tract infection

AU - Hara, Kohei

AU - Hirota, Masaki

AU - Yamaguchi, Keizo

AU - Kohno, Shigeru

AU - Hayashi, Toshiaki

AU - Doutsu, Yasumasa

AU - Watanabe, Kouichi

AU - Mukai, Hiroshi

AU - Inoue, Yuuichi

AU - Nakata, Koichiro

AU - Nakatani, Tatsuo

AU - Nakamori, Yoshitaka

AU - Chonabayashi, Naohiko

AU - Noguchi, Masayuki

AU - Narui, Kohji

AU - Saito, Akira

AU - Tomizawa, Masumi

AU - Nakayama, Ichiro

AU - Irimajiri, Shoichiro

AU - Obana, Mitsuo

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Aonuma, Seiichi

AU - Motomiya, Masakichi

AU - Konno, Kiyoshi

AU - Nagai, Kohsaku

AU - Shimoda, Shigeru

AU - Hayashi, Izumi

AU - Ohnuma, Kikuo

AU - Hasuike, Miki

AU - Katsu, Masataka

AU - Okui, Shinji

AU - Fukui, Toshio

AU - Hirose, Hiroshi

AU - Kobayashi, Hiroyuki

AU - Oshitani, Hiroshi

AU - Shimada, Jingoro

AU - Shiba, Kohya

AU - Kaji, Masanobu

AU - Saito, Atsushi

AU - Sakai, Osamu

AU - Shimada, Kaoru

AU - Inamatsu, Takashi

AU - Ikemoto, Hideo

AU - Watanabe, Kazuyoshi

AU - Kohara, Tomoo

AU - Ohkubo, Takao

AU - Ikeda, Hirotada

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Murohashi, Kou

AU - Sato, Atuhiko

AU - Okano, Akihiko

AU - Okano, Hirokazu

AU - Taniguchi, Masami

AU - Miki, Fumio

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Hino, Jiro

AU - Nakagawa, Yoshihisa

AU - Matsushima, Toshiharu

AU - Tano, Yoshihiko

AU - Yamakido, Michio

AU - Ishioka, Shinichi

AU - Nasu, Masaru

AU - Yamazaki, Tohru

AU - Shigeno, Hideaki

AU - Goto, Jun

AU - Tashiro, Takayoshi

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Rikitomi, Naoto

AU - Oishi, Kazunori

AU - Saito, Atsushi

AU - Shigeno, Yoshihiro

AU - Irabu, Yuei

AU - Kohatsu, Hiroshi

AU - Ohshiro, Junichi

AU - Ogawa, Nobuya

AU - Deguchi, Koichi

PY - 1990

Y1 - 1990

N2 - To objectively evaluate the appropriate clinical dose of fleroxacin, a new quinolone antibacterial agent, in the treatment of chronic respiratory tract infections, we carried out a dose-finding comparative study using ofloxacin (OFLX) as the control drug. Patients were given fleroxacin at a single daily dose of 200 mg or 300mg or 600mg of OFLX (t. i. d.) for 14 days in principle. The following results were obtained. 1. The clinical efficacy rates (including excellent and good) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 90.0%(36/40) in the fleroxacin 300 mg group and 77.3%(34/44) in the OFLX group. There was a significant difference between the 200 mg and 300 mg fleroxacin groups. 2. Bacteriologically, the eradication rates were 65.4%(17/26) in the fleroxacin 200 mg group, 73.9%(17/23) in the fleroxacin 300 mg group and 75.9%(22/29) in the OFLX group. 3. The incidence of side effects was 8.5%(4/47) in the fleroxacin 200 mg group, 9.5%(4/42) in the fleroxacin 300 mg group and 4.3%(2/46) in the OFLX group. They were not serious in degree. 4. The incidence of abnormal changes in laboratory test values was 7.1%(3/42) in the fleroxacin 200 mg group, 8.3%(3/36) in the fleroxacin 300 mg group and 25.6%(11/43) in the OFLX group. All changes were mild in degree. 5. The utility rates (including markedly useful and useful) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 85.4%(35/41) in the fleroxacin 300 mg group and 75.6%(34/45) in the OFLX group. There was a significant difference between the 200mg and 300 mg fleroxacin groups. Our results suggest that a daily dose of 300mg of fleroxacin is a suitable clinical dosage in treating chronic respiratory tract infections.

AB - To objectively evaluate the appropriate clinical dose of fleroxacin, a new quinolone antibacterial agent, in the treatment of chronic respiratory tract infections, we carried out a dose-finding comparative study using ofloxacin (OFLX) as the control drug. Patients were given fleroxacin at a single daily dose of 200 mg or 300mg or 600mg of OFLX (t. i. d.) for 14 days in principle. The following results were obtained. 1. The clinical efficacy rates (including excellent and good) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 90.0%(36/40) in the fleroxacin 300 mg group and 77.3%(34/44) in the OFLX group. There was a significant difference between the 200 mg and 300 mg fleroxacin groups. 2. Bacteriologically, the eradication rates were 65.4%(17/26) in the fleroxacin 200 mg group, 73.9%(17/23) in the fleroxacin 300 mg group and 75.9%(22/29) in the OFLX group. 3. The incidence of side effects was 8.5%(4/47) in the fleroxacin 200 mg group, 9.5%(4/42) in the fleroxacin 300 mg group and 4.3%(2/46) in the OFLX group. They were not serious in degree. 4. The incidence of abnormal changes in laboratory test values was 7.1%(3/42) in the fleroxacin 200 mg group, 8.3%(3/36) in the fleroxacin 300 mg group and 25.6%(11/43) in the OFLX group. All changes were mild in degree. 5. The utility rates (including markedly useful and useful) as judged by the committee were 62.2%(28/45) in the fleroxacin 200 mg group, 85.4%(35/41) in the fleroxacin 300 mg group and 75.6%(34/45) in the OFLX group. There was a significant difference between the 200mg and 300 mg fleroxacin groups. Our results suggest that a daily dose of 300mg of fleroxacin is a suitable clinical dosage in treating chronic respiratory tract infections.

KW - Chronic respiratory tract infection

KW - Dose-finding study

KW - Fleroxacin

UR - http://www.scopus.com/inward/record.url?scp=0025612210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025612210&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.Supplement2_454

DO - 10.11250/chemotherapy1953.38.Supplement2_454

M3 - Article

AN - SCOPUS:0025612210

SN - 0009-3165

VL - 38

SP - 454

EP - 471

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Dose-finding study on fleroxacin in chronic respiratory tract infection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this